RxDoctor Payments Data

Ann Gonzalez

Family · Langhorne, PANPI 1083116230

Payments from drug & device makers

$6,796in general payments, 2019–2025

Across 381 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$843
  • AbbVie$701
  • AstraZeneca$648
  • Amgen$586
  • Lilly USA, LLC$533
  • Pfizer$445
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,796100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,796 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$36,405
Medicare patients
211
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide26$26,963
EliquisApixaban31$26,662
OzempicSemaglutide24$24,829
JanuviaSitagliptin Phosphate17$20,609
FarxigaDapagliflozin Propanediol15$19,041
JardianceEmpagliflozin17$18,056
Atrovent HfaIpratropium Bromide16$7,241
Spiriva RespimatTiotropium Bromide11$5,556
Levothyroxine Sodium151$1,943
Albuterol Sulfate HfaAlbuterol Sulfate66$1,877
Atorvastatin Calcium202$1,795
Pravastatin Sodium104$1,649
Rosuvastatin Calcium80$1,436
Valsartan16$1,123
Metoprolol Succinate73$972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$843$51,79250 claims
PfizerEliquis$445$26,66231 claims
Boehringer IngelheimJardiance, Spiriva Respimat$233$23,61228 claims
MerckJanuvia$235$20,60917 claims
AstraZenecaFarxiga$648$19,04115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →